LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Slēgts

SektorsVeselības aprūpe

14.6 2.38

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

14.26

Max

14.63

Galvenie mērījumi

By Trading Economics

Ienākumi

-1.8B

14B

Pārdošana

392M

85B

P/E

Sektora vidējais

18.205

35.733

Dividenžu ienesīgums

0.64

Peļņas marža

16.496

Darbinieki

27,811

EBITDA

-622M

25B

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.64%

3.13%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-164M

12B

Iepriekšējā atvēršanas cena

12.22

Iepriekšējā slēgšanas cena

14.6

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 23. jūl. 17:49 UTC

Peļņas

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

2025. g. 23. jūl. 17:48 UTC

Peļņas

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

2025. g. 23. jūl. 17:48 UTC

Peļņas

Dr Reddy's Labs 1Q Rev $85.45B >RDY

2025. g. 9. maijs 18:56 UTC

Peļņas

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

2025. g. 9. maijs 18:56 UTC

Peļņas

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

2025. g. 23. janv. 17:46 UTC

Peļņas

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

2025. g. 23. janv. 17:42 UTC

Peļņas

Dr. Reddy's 3Q Rev INR83.59B

2024. g. 5. nov. 11:01 UTC

Peļņas

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

2024. g. 5. nov. 11:00 UTC

Peļņas

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

2024. g. 5. nov. 10:57 UTC

Peļņas

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

2024. g. 5. nov. 10:57 UTC

Peļņas

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

Salīdzinājums

Cenas izmaiņa

Dr Reddy's Laboratories Ltd-ADR Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 13.84Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
help-icon Live chat